Assembly Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Assembly Biosciences, Inc. (ASMB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -10.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-19
- Assembly Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -10.00%.
- Assembly Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -8.40%.
- Assembly Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -1.70%.
- Assembly Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -2.90%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -10.00% 10-K · filed 2026-03-19 | |
| 2024-12-31 | -8.40% 10-K · filed 2026-03-19 | |
| 2023-12-31 | -1.70% 10-K · filed 2025-03-20 | |
| 2022-12-31 | -2.90% 10-K · filed 2024-03-28 | |
| 2021-12-31 | -4.50% 10-K · filed 2023-03-22 | |
| 2020-12-31 | 0.70% 10-K · filed 2022-03-11 | |
| 2019-12-31 | -3.80% 10-K · filed 2021-02-25 | |
| 2018-12-31 | 6.70% 10-K · filed 2021-02-25 | -6.70% 10-K · filed 2019-02-28 |
| 2017-12-31 | 0.00% 10-K · filed 2020-03-04 | |
| 2016-12-31 | 3.40% 10-K · filed 2019-02-28 | |
| 2015-12-31 | 16.70% 10-K · filed 2018-03-08 | |
| 2014-12-31 | 0.00% 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |